FMGE December 2023 Exam To Be held On 20th January, Details

Delhi: The Foreign Medical Graduate Examination (FMGE) December 2023 exam is going to be conducted on 20th January 2024. The result is expected to be declared by 20th February 2024.

In the month of November 2023, the National Board of Examinations (NBE) released the detailed schedule for FMGE. It shall be conducted at various exam centres engaged for the purpose. Only eligible candidates will be allowed to appear in the FMGE who have both the Eligibility Certificate (if applicable) and the Provisional Pass Certificate/Degree Certificate of Primary Medical Qualification.

Candidates who fail to submit the documents as prescribed in the Information Bulletin for FMGE will not be allowed to appear in the examination and will be declared ineligible to appear.

Admit Cards for the FMG Examination shall be available to download at the NBEMS website from 12th January 2024 onwards. Candidates found ineligible before the conduct of the examination shall not be issued admit cards. Candidates will be informed through SMS/Email alerts and website notices regarding the availability of the admit card on the NBEMS website. Admit cards will not be sent to the candidates by Post/Email.

Candidates are required to download their admit card from the NBEMS website and affix firmly their recent (not more than 3 months old) passport-size photograph in the space provided on the admit card.

Also Read:NBE Notifies on Selective, Final Edit Window For FMGE December 2023 applications, all details here

Exam pattern –

The examination consists of one paper comprising 300 multiple-choice questions. Each question shall have 4 response options/distractors in English language only. Candidates are required to select the correct/best/most appropriate response/answer out of the 4 response options provided in each question. FMGE is divided into two parts of 150 questions, each with a time allocation of 150 minutes for each part. There is a scheduled break between the two parts.

The examination shall be a multiple-choice questions (MCQs) test delivered using a computer network as per the prescribed scheme. Negative Marking: There shall be no negative marking.

A candidate shall be declared as having passed only if he/she obtains a minimum of 150 marks out of 300 in the examination. Results (Pass/Fail) for eligible candidates will be displayed on the NBEMS website. There is no provision for re-totaling/reevaluation.

A demo test shall be available for the benefit of candidates to familiarise themselves with the Computer Based Test format on the website of NTA. Candidates will be able to access the Demo test tentatively from 10th January 2024 onwards.

The
following schedule will be followed on the exam day –

Activities

Part – I

(9:00 AM
– 11:30 AM)

Part – II

(2:00 PM
– 04:30 PM)

Allow
Candidates to enter the examination centre and Commence Registration

07:00 AM

12:00 PM

Entry
closes at the Examination Center

08:30 AM

01:30 PM

Grant
access for Candidate Login

08:45 AM

01:45 PM

Candidates
log in to read instructions

08:50 AM

01:50 PM

Exam
Start Time

09:00 AM

02:00 PM
Also Read:JIPMER To Conduct Workshop On Communication Skills For Interns, all details here

Powered by WPeMatico

Lilly launches end to end digital healthcare experience through LillyDirect

Indianapolis: Eli Lilly and Company has announced LillyDirect, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes. LillyDirect offers disease management resources, including access to independent healthcare providers, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing services.

“A complex U.S. healthcare system adds to the burdens patients face when managing a chronic disease. With LillyDirect, our goal is to relieve some of those burdens by simplifying the patient experience to help improve outcomes,” said David A. Ricks, Lilly‘s chair and CEO. “LillyDirect offers more choices in how and where people access healthcare, including a convenient home delivery option to fill Lilly medicines they have been prescribed.”

For patients living with obesity, migraine and diabetes, LillyDirect offers:

  • LillyDirect Pharmacy Solutions, a digital pharmacy for select Lilly medicines powered by third party online pharmacy fulfillment services. LillyDirect Pharmacy Solutions gives patients a simple option to get consistent access to Lilly medicines they have been prescribed with the added convenience of home delivery. By obtaining medicines directly from Lilly, patients can easily access Lilly‘s affordability solutions and savings card opportunities are automatically applied for patients who qualify. Medicines fulfilled by pharmacy service providers through LillyDirect Pharmacy Solutions ship free of charge.
  • Disease state and healthcare educational information to help empower and support patients on their care journeys.
  • Access to independent telehealth providers that could complement a patient’s current primary care team or be an alternative to in-person care for certain conditions.
  • An independent search tool that allows a patient to find healthcare professionals near them if they prefer in-person care.

“We know that people have come to depend on the efficiency and convenience of digital solutions to meet a variety of their everyday needs – healthcare being one of them,” said Frank Cunningham, group vice president, global value and access at Lilly. “We launched LillyDirect with the hope that it will offer patients an innovative end-to-end experience to manage their health and access their medicines, so they can get back to living their lives.”

Read also: Eli Lilly concludes acquisition of POINT Biopharma

Powered by WPeMatico

NBE Grants Final Opportunity To FMGE Dec 2023 Candidates To Submit Deficient Documents, Details

Delhi : Through a recent notice, NBE (National Board of Examinations in Medical Sciences) has given final opportunity to FMGE Dec 2023 candidates to submit deficient documents.

In line with the clause 2.8.3 and 8.30.2 of the Information Bulletin for FMGE Dec 2023, the list of candidates who have failed to rectify the deficiencies related to the following documents even by 1st January 2024 is published herein below:

a. Primary Medical Qualification Degree certificate/Provisional Pass Certificate duly apostilled/attested by the Embassy of India in the country from where the primary medical qualification has been obtained

b. Eligibility Certificate issued by the NMC/MCI (If applicable)/ Admission Letter/ Proof of qualifying NEET-UG

c. Proof of Citizenship

d. Mismatch in Name/Date of Birth in documents submitted

e. Supportive documents for transfer from one medical institution to another

f. Mark sheet of standard 12th and Caste certificate (SC/ST/OBC)

Click below for the list of candidates who have failed to submit deficient documents

 https://medicaldialogues.in/pdf_upload/natboard-datapublicnoticeuploadedfilefile202401059373-229434.pdf

Final opportunity to submit the documents is being given during 05.01.2024 (12:00 PM onwards) to 08.01.2024 (till 11:55 PM)

Documents can only be submitted through the Online Deficient Document Submission Portal which can be accessed through weblink:

It is once again reiterated that pursuant to the recommendations of the National Medical Commission and approval of the Ministry of Health and Family Welfare (MoHFW), Govt. of India,only eligible candidates will be allowed to appear in the FMGE who have both the Eligibility Certificate (if applicable) and the Provisional Pass Certificate/Degree Certificate of Primary Medical Qualification.

In terms of clause 2.8.4 and 8.30.3 of the Information Bulletin for FMGE December 2023, candidates who fail to submit duly completed applications with requisite documents and/or fail to rectify the deficiencies in their applications by the last date prescribed for rectification shall be declared ineligible. Admit Card shall not be issued to candidates who are declared ineligible before the conduct of the examination.

Candidates who will fail to submit the required documents shall be declared INELIGIBLE for FMGE December 2023 session. No further opportunity to submit documents shall be given.

For any query, please contact NBEMS Candidate Care Support at 011-45593000 or write to National Board of Examinations in Medical Sciences at its Communication Web Portal 

To view the official Notice, Click here :  https://medicaldialogues.in/pdf_upload/natboard-datapublicnoticenotice202401057095-229435.pdf

Powered by WPeMatico

J&K High Court directs 45 SKIMS employees service regularization

Srinagar: In a landmark verdict, the High Court of Jammu and Kashmir and Ladakh has directed the regularization of services for employees of the Sher-e-Kashmir Institute of Medical Sciences (SKIMS) from their initial appointment date. This significant ruling comes as a relief to 45 petitioner-employees serving as Staff Nurses on a contractual basis.

Justice Chowdhary pointed out that the court has taken note of the violation of Articles 14 and 16 of the Constitution of India and stated, “It emerges from the facts of the case that two groups of similarly situated employees were considered, and one group was accorded the benefit of regularisation, whereas the petitioners were discriminated against.”

Also Read:Timely Publication of Medical College Assessment Reports on NMC Website: Plea in Madras HC

The court’s decision challenges Government Order No 15-SKIMS of 2013, which previously regularized services from the order’s issuance date (March 19, 2013). According to a report by The Daily Excelsior, the petitioner-employees successfully argued for regularization from their initial appointments under SRO 255 dated August 5, 2003, specifically against migrant vacancies. This aligns their regularization process with other contractual employees who have been granted similar treatment.

Justice M A Chowdhary nullified the contested order and decreed the regularisation of employees from the date of their initial appointment, as stipulated under SRO 255 dated August 05, 2003. Furthermore, SKIMS authorities are now mandated to extend all consequential benefits resulting from the retrospective regularisation. The court’s scrutiny revealed a failure by SKIMS authorities to delineate why contract Staff Nurses, similarly situated and engaged against migrant vacancies, had not been subjected to retrospective regularisation. This discriminatory oversight prompted the court to underscore the unjust denial of equal employment opportunities to the petitioners compared to their counterparts in public service, reports the Daily. 

The court stated that the petitioners have been discriminated against considering that SKIMS authorities have not given them the similar benefits which have been enjoyed by their counterparts, instead, the cases of these employees were deferred for unknown reasons.“The orders impugned are bad in law, in as much as regularization of services of petitioners must relate to the date of their initial appointment; that due to the delay caused in regularizing the services of the petitioners, the petitioners have suffered a lot as they were entitled to be regularized from the date they were initially appointed, however, their cases have been wilfully delayed”, read the judgment.

This court decision not only ensures justice for SKIMS employees but also sets a precedent for equitable employment practices, emphasizing the need for fair treatment and equal opportunities in the realm of public employment. The ruling stated that the petitioners were entitled to regularisation from their initial appointment and declared the contested orders to be legally invalid. 

Also Read: Dr Jitendra Singh reviews pace of work on AIIMS Jammu; issues instructions to administration and CPWD

Powered by WPeMatico

NMC tells Medical Colleges to Submit NEET SS Admission Info, Online Portal to Remain Open till 10th January

New Delhi: The Postgraduate Medical Education Board (PGMEB) of the National Medical Commission (NMC) has asked the medical institutes to fill in the requisite NEET-SS admission data on the online portal.

Issuing a public notice in this regard, the PG Board of NMC has informed that the online portal for filling up the details of students who got admitted to the Super-Speciality courses shall remain open from 5th to 10th January 2024.

The Commission has clarified that “No physical/ manual data will be accepted whatsoever is the reason.”

Referring to the notice issued by the Medical Counselling Committee (MCC) dated 30.12.2023, NMC PG Board mentioned that the students have to report by 6.00 p.m. of 05.01.2024 after the 2 nd round of Counselling.

“Accordingly, all the Medical Colleges/ Institutes in India under the Commission are hereby informed that the online portal for filling up the details of candidates who took admission in Super Specialty Courses, shall be opened from 5th to 10th January, 2024,” NMC PGMEB mentioned in the notice.

“All are requested to fill in the requisite data in the stipulated time,” the notice mentioned, adding that the “onus of furnishing true, correct and authentic information is upon the College concerned and in case of furnishing of any wrong/incorrect information it shall be open to NMC to initiate action as is permissible in law.”

In case of any difficulty in accessing the NMC website, the colleges have been asked to send an email to support.pgmonitoring@nmc.org.in and thereafter the Commission office shall revert within 02 working days to resolve the query/issue.

Earlier, with respect to MBBS admissions, the Undergraduate Medical Education Board (UGMEB) of NMC clarified that the students who have not registered in the NMC portal shall be considered as invalid admissions and such admissions shall not be eligible for future registration processes as well.

The Apex Medical Commission had informed that only those MBBS students who have registered in the NMC portal shall be considered to be valid admissions.

Releasing the list containing the details of MBBS students admitted in this academic year, the UG Board of NMC had asked the students, who were admitted to MBBS course in the academic year 2023-2024 and whose details are not reflected in the list, to contact the Directorate of Medical Education/ Counselling Authority urgently.

To view the notice, click on the link below:

https://medicaldialogues.in/pdf_upload/neet-ss-admission-data-229431.pdf

Also Read: MBBS Admissions not uploaded on the NMC Portal will be considered INVALID

Powered by WPeMatico

Merck announces Phase 3 trial initiations for 4 investigational candidates from its hematology, oncology pipeline

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of pivotal Phase 3 trials for four of its investigational candidates from its diverse pipeline in hematologic malignancies and solid tumors. Global Phase 3 studies have been initiated and are actively enrolling for the following investigational candidates:

  • Bomedemstat, an investigational orally available lysine-specific demethylase 1 (LSD1) inhibitor, being evaluated for the treatment of certain patients with essential thrombocythemia (ET);
  • Nemtabrutinib, an investigational oral, reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, being evaluated for the treatment of certain patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL);
  • MK-2870, an investigational trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) being developed in collaboration with Kelun-Biotech, which is being evaluated for certain patients with non-small cell lung cancer (NSCLC) and certain patients with previously treated endometrial carcinoma;
  • and MK-5684, an investigational CYP11A1 inhibitor being developed in collaboration with Orion, which is being evaluated for the treatment of certain patients with metastatic castration-resistant prostate cancer (mCRPC).

Read also: USFDA grants priority review to Merck investigational 21-valent Pneumococcal Conjugate Vaccine specifically designed to protect adults

“These Phase 3 trial initiations for four of our investigational candidates represent a critical step forward in our efforts to advance potential treatment options for people with solid tumors and hematologic neoplasms and malignancies,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “We have a proud legacy of turning breakthrough science into medicines that save and improve lives around the world, and we are dedicated to continuing research to expand our broad portfolio of oncology therapeutics to continue to address unmet needs in cancer care.”

Read also: Merck gets European Commission nod for two new indications for Keytruda in gastrointestinal cancers

Powered by WPeMatico

Bond Service allotment in Maharashtra: DMER notifies on 1140 Vacancies For PG Degree Holders, details

Maharashtra:
The Directorate of Medical Education & Research (DMER Maharashtra) has
released the vacancy details for online allotment of Government Social
responsibility service (Bond Service) to PG Degree holders.

1140 vacancies are there for online allotment of Government Social
responsibility services to PG Degree holders.

Detailed seat matrix –

Bhagwati Hosp. N. T. C. Bldg. Boriwali (W)

10

BHARATRATNA DR. BABASAHEB AMBEDKAR HOSPITAL

10

BHGMC DHULE

58

GGMC MUMBAI

29

GMC AKOLA

52

GMC BARAMAT

46

GMC CHANDRAPUR

76

GMC GONDIA

78

GMC JALGAON

83

GMC KOLHAPUR

45

GMC LATUR

26

GMC MIRAJ

43

GMC NAGPUR

33

GMC NANDURBAR

48

GMC Sindhudurg

50

GOVERNMENT MEDICAL COLLEGE, ALIBAG-RAIGAD

41

Government Medical College, Parbhani

20

Government Medical College, Ratnagiri

31

GSMC & KEM HOSPITAL

13

IGGMC NAGPUR

23

K.B.BHABHA MUNICIPAL GENERAL HOSPITAL ,BANDRA

10

KASTURBA HOSPITAL FOR INFECTION DISES

3

KHAN BAHADUR BHABHA HOSPITAL, KURLA WEST MUMBAI 70

11

Krantiveer Mahatma Jyotiba Phule Hosp., Vikhroli (E)

6

KRATNIJYOTI SAVITRIBAI PHULE HOSPITAL, BORIVALI EAST MUMBAI

7

LTMC & SION HOSPITAL

21

Maa. Hosp. Chembur

1

MANOHAR WAMANRAO DESAI MUNICIPAL GENERAL HOSPITAL

9

PT MADAN MOHAN MALAVIYA SHATABDI HOSPITAL GOVANDI MUMBAI

12

Rajawadi Hosp. Ghatkoper (E)

20

S.V.D.SAVARKAR MUNICIPAL GEN.HOSPITAL MULUND EAST

7

SANT MUKTABAI MUNCIPAL GENERAL HOSPITAL,BARVENAGAR,GHATKOPAR

7

SIDDHARTH MUNICIPAL GENERAL HOSPITAL

9

SMT. MANSADEVI TULSIDAS AGARWAL HOSPITAL

12

SRTR BEED

54

TNMC & NAIR HOSPITAL

8

V N DESAI MUNICIPAL GENERAL HOSPITAL

7

VMMC SOLAPUR

52

VNMC YAVATMAL

69

Also Read:AIIMS Announces Round 2 counselling results of INI SS January 2024 Session

The detailed counselling schedule –

The candidates can fill out the online application form and
preferences up to 09.01.2024 up to 11.59 PM. On 10.01.2024 by evening, the
declaration of allotment of bond service to the candidate and issue of
recommendation letter web portal through login ID will be done.

To view the notice, click on the link below –

https://medicaldialogues.in/pdf_upload/vacancy-dated-04012024-229385.pdf

Also Read:Stipend hike for Nursing, Pharma, Allied Health students in Odisha, BSc Nursing students to get Rs 5000 during internship

Powered by WPeMatico

Final PGMER 2023 Regulations released in Gazette

Around four months after the Draft was released, the final Post-Graduate Medical Education Regulations, 2023 (PGMER 2023) have now been published. These Regulations, which have come into force from the date of their publication in the official gazette i.e. 29.12.2023, lay down the rules and regulations regarding admission, counselling, and other details related to the postgraduate medical courses.

For more details, check out the link given below:

Final PGMER 2023 Regulations Released In Gazette, Details

Powered by WPeMatico

Medtronic gets CE Mark for next generation Micra leadless pacing systems

Dublin: Medtronic plc has announced it has received CE (Conformité Européenne) Mark for its Micra AV2 and Micra VR2, the next generation of its miniature, leadless pacemakers.

Micra AV2 and Micra VR2, the world’s smallest pacemakers, provide longer battery life and easier programming than prior Micra pacemakers, while still delivering the many benefits of leadless pacing such as reduced complications compared to traditional pacemakers.

With approximately 40% more battery life compared to previous generations, Medtronic projects the battery life of Micra AV2 and Micra VR2 is nearly 16 and 17 years, respectively. This means more than 80% of patients who receive a Micra may only require one device for life.

This CE Mark milestone follows U.S. Food and Drug Administration approval for the Micra AV2 and VR2 devices in 2023.

In addition to size and longevity benefits, Micra devices are also the only leadless pacemakers with remote monitoring capabilities, which allow a doctor or clinic to check on a patient’s heart device without the need for a patient to travel to their clinic for an in-person appointment. Other patient benefits of remote monitoring may include a reduction in hospitalizations and increase in sense of security.

“For more than eight years, our Micra leadless pacemakers have provided meaningful benefits to people in Europe who require a pacemaker. Now, these patients have access to the latest leadless pacing technology that, for most of them, may be the only device they will ever need,” said Robert C. Kowal, M.D., Ph.D., general manager, Cardiac Pacing Therapies within the Cardiac Rhythm Management business, which is part of the Cardiovascular Portfolio at Medtronic.

“The first generation of leadless Micra pacemakers demonstrated a significant reduction in major complications, and this next generation of Micra brings several additional benefits including greater longevity, and specifically for the Micra AV2, new algorithms to optimize AV synchrony at faster heart rates while requiring less in-office programming,” said Prof. Dr. Christophe Garweg, Cardiologist at University Hospitals of Leuven, Belgium. “These advantages likely will expand the use of the leadless pacemaker to more patients.”

Globally, more than 200,000 patients have received Micra pacemakers. Comparable in size to a large vitamin, Micra pacemakers are less than one-tenth the size of traditional pacemakers. Unlike traditional pacemakers, Micra pacemakers do not require leads or a surgical “pocket” under the skin, so potential sources of complications related to leads and pockets are eliminated, and there is no visible sign of the device.

Read also: Medtronic bags USFDA nod for PulseSelect Pulsed Field Ablation System to treat atrial fibrillation

Powered by WPeMatico

Faricimab outperforms anti-VEGF Drugs in DME and AMD Treatment by improving central subfoveal thickness

In the industrialized world, Neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) cause blindness. Faricimab, launched in the US in January 2022, treats diabetic macular edema and wet age-related macular degeneration. Based on evidence from Systematic reviews, anti-VEGF agents’ are advantageous in AMD and DME compared to other therapies.

In a study published in the Medicine (Baltimore), researchers found Faricimab to be significantly advantageous in improving central subfoveal thickness (CST) and reducing injection numbers for DME and AMD patients compared to other anti-VEGF drugs, with high-strength and moderate-strength evidence, respectively.
The review evaluated and compared Faricimab’s safety and efficacy against VEGF therapy for neovascular AMD and DME. They conducted a literature search of electronic databases for RCTs of Faricimab for AMD and DME from 2013 to 2023 and used weighted mean differences and risk ratios to combine the studies.
Study results include the following points:
· 4 RCTs with 1678 AMD patients and 3 RCTs with 20 DME patients were included.
· In AMD patients, a significant difference was found in the number of injections between Faricimab and other anti-VEGF therapy with MD −2.42.
· No significant differences were found for change in BVCA, CST , gaining 15 or more letters, or adverse events.
· In DME patients, a significant difference was observed for CST (MD = −22.41) and the number of injections (MD = −0.93).
· No significant differences were found for BVCA change, gaining 15 or more letters, or for adverse events.
The study established a reference for the clinical application of faricimab, which blocks VEGF through Ang-2 and VEGF-A to promote vascular stability. Faricimab’s effectiveness in improving anatomical outcomes and extending durability with dosing every 16 weeks addresses the need for durable therapies optimizing real-world outcomes.
Reference:
Li G, Zhu N, Ji A. Comparative efficacy and safety of Faricimab and other anti-VEGF therapy for age-related macular degeneration and diabetic macular edema: A systematic review and meta-analysis of randomized clinical trials. Medicine (Baltimore). 2023 Dec 15;102(50):e36370.

Powered by WPeMatico